DPM Stock Chart & Stats
€10.10
€0.04(1.18%)
At close: 4:00 PM EST
€10.10
€0.04(1.18%)
Day’s Range― - ―
52-Week Range€6.50 - €18.80
Previous CloseN/A
Volume137.00
Average Volume (3M)118.00
Market Cap
€3.09B
Enterprise Value€1.00M
Total Cash (Recent Filing)€44.31B
Total Debt (Recent Filing)€217.19B
Price to Earnings (P/E)4.8
Beta1.30
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)268.99
Shares Outstanding449,204,560
10 Day Avg. Volume125
30 Day Avg. Volume118
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.07Price Target Upside-20.08% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)1.14
Revenue Forecast (FY)€2.91B
Bulls Say, Bears Say
Bulls Say
Profitability ReboundA sharp profitability recovery in 2026 with healthy operating and net margins indicates the company can generate sustainable operating earnings versus prior losses. Higher margin quality supports internal funding for R&D, commercialization and reduces reliance on external financing over the medium term.
Improved LeverageMaterial de-leveraging and ROE recovery enhance financial flexibility and lower interest burden, improving capacity to invest in pipeline and partnerships. A healthier capital structure increases resilience to shocks and supports strategic choices across a 2–6 month horizon and beyond.
Diversified Pharma Revenue ModelMultiple revenue streams—domestic and international product sales plus licensing/milestones and contract manufacturing—reduce single-product dependency. This structural diversity supports steadier cash inflows across product lifecycles and strengthens long-term commercial resilience.
Bears Say
Volatile Revenues & EarningsLarge swings in top-line and earnings across recent years undermine predictability of future results, complicating forecasting and capital allocation. Persistent revenue/earnings volatility makes sustaining R&D programs, commercial investments and partner confidence more difficult over medium-term planning horizons.
Inconsistent Cash GenerationIrregular free cash flow and past major outflows raise risk that internal funds may be insufficient for sustained R&D or capex without external financing. This inconsistency increases the chance of funding-driven delays to development programs or reliance on dilutive or costly capital sources.
Prior Elevated Leverage & Asset DeclineHistoric periods of very high leverage and shrinking asset bases reduce headroom for strategic moves and heighten refinancing risk if conditions worsen. Even with recent improvement, legacy balance-sheet weakness can constrain M&A, licensing flexibility and long-term investment capacity.
Sumitomo Dainippon Pharma Co News
DPM FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was €6.50 and its highest was €18.80 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is €3.09B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date is Jul 31, 2026 which is in 5 days.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Sumitomo Dainippon Pharma Co Ltd released its earnings results on May 13, 2026. The company reported -€0.011 earnings per share for the quarter, beating the consensus estimate of -€0.082 by €0.071.
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd does not currently pay dividends.
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Sumitomo Dainippon Pharma Co Ltd reported an EPS of -€0.011 in its last earnings report, beating expectations of -€0.082. Following the earnings report the stock price went down -0.035%.
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in DE:DPM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
DPM Company Deck
DPM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlighted promising developments in the oncology and regenerative medicine pipelines but was overshadowed by significant financial losses, decreased revenue across all segments, and underperformance of key products, leading to a revised downward financial forecast. The call focused on strategic adjustments to address market challenges and improve profitability.View all DE:DPM earnings summariesDPM Stock 12 Month Forecast
Average Price Target
€8.07
▼(-20.08% Downside)
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―